Entero Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
EBITDA | -638 | -930 | -1,203 |
Net Income | -998 | -1,259 | -12,238 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -54 | -818 | -171 |
Cash | 4 | 59 | 163 |
Basic Shares | 4,765 | 4,765 | 4,754 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -29 | -106 | -537 | |
EBITDA | 33 | -15,743 | -14,584 | -57,989 |
EBIT | -15 | -15,772 | -14,613 | -58,531 |
Net Income | -18,059 | -15,794 | -14,629 | -58,537 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -9,217 | -12,877 | -22,344 | -42,607 |
Cash | 163 | 3,711 | 1,362 | 8,248 |
Basic Shares | 3,434 | 336 | 35 | 2 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.48 |
2025-03-31 | -$0.28 |
2024-12-31 | -$2.59 |
2024-09-30 | -$0.58 |
